New Use
Daprodustat effectively reduces fatigue in non-dialysis subjects with chronic kidney disease anemia by targeting specific hepcidin and hsCRP levels, achieving significant improvements in patient-reported vitality measures.
Patent Information
- Application Number
- JP2025534490
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-12-13
- Filing Date
- 2023-12-11
- Publication Date
- 2025-12-05
AI Technical Summary
Current treatments for anemia associated with chronic kidney disease do not consistently result in clinically meaningful improvements in patient-reported outcomes such as reduced fatigue, and the relationship between hemoglobin concentration and vitality improvements is weak.
Daprodustat or its pharmaceutically acceptable salts are used to treat anemia in non-dialysis subjects with chronic kidney disease, targeting specific baseline hepcidin and hsCRP levels to reduce fatigue, with treatment durations of at least 12 weeks and hemoglobin levels maintained in the range of 10-12 g/dL.
Daprodustat significantly reduces fatigue in non-dialysis subjects with anemia, demonstrated by a 6-point or greater increase in the SF-36 vitality domain and an 8-point or greater increase in the CKD-AQ fatigue/low energy/weakness domain, indicating clinically relevant improvements.